Kristina Krasnikova

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.

Cooley advised Cellares, the first integrated development and manufacturing organization dedicated to clinical and industrial-scale cell therapy manufacturing, on its $255 million financing.

Cooley advised Kriya, a biopharmaceutical company, on the close of its Series C extension at more than $150 million in committed and raised capital, bringing the total Series C financing round to more than $430 million.

Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.